Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Megumu Fukunaga

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Clinical Journal of the American Society of Nephrology : CJASN|April 12, 2014
Comparison of methylprednisolone plus prednisolone with prednisolone alone as initial treatment in adult-onset minimal change disease: a retrospective cohort studyMaki Shinzawa, Ryohei Yamamoto, Yasuyuki Nagasawa, et al.
Clinical and Experimental Nephrology|March 21, 2013
Age and prediction of remission and relapse of proteinuria and corticosteroid-related adverse events in adult-onset minimal-change disease: a retrospective cohort studyMaki Shinzawa, Ryohei Yamamoto, Yasuyuki Nagasawa, et al.
Journal of the American Society of Nephrology : JASN|January 30, 2004
The SOD mimetic tempol ameliorates glomerular injury and reduces mitogen-activated protein kinase activity in Dahl salt-sensitive ratsAkira Nishiyama, Masanori Yoshizumi, Hirofumi Hitomi, et al.
Plos One|May 17, 2011
Mutation analysis of 2009 pandemic influenza A(H1N1) viruses collected in Japan during the peak phase of the pandemicJean-Étienne Morlighem, Shintaro Aoki, Mami Kishima, et al.
Scientific Reports|June 13, 2022
Predictors of early remission of proteinuria in adult patients with minimal change disease: a retrospective cohort studyRyohei Yamamoto, Enyu Imai, Shoichi Maruyama, et al.
Journal of Nephrology|April 2, 2022
Time to remission of proteinuria and incidence of relapse in patients with steroid-sensitive minimal change disease and focal segmental glomerulosclerosis: the Japan Nephrotic Syndrome Cohort StudyRyohei Yamamoto, Enyu Imai, Shoichi Maruyama, et al.
Clinical and Experimental Nephrology|August 12, 2022
Deep learning analysis of clinical course of primary nephrotic syndrome: Japan Nephrotic Syndrome Cohort Study (JNSCS)Tomonori Kimura, Ryohei Yamamoto, Mitsuaki Yoshino, et al.
Clinical and Experimental Nephrology|April 22, 2018
Regional variations in immunosuppressive therapy in patients with primary nephrotic syndrome: the Japan nephrotic syndrome cohort studyRyohei Yamamoto, Enyu Imai, Shoichi Maruyama, et al.
Clinical and Experimental Nephrology|March 9, 2020
Incidence of remission and relapse of proteinuria, end-stage kidney disease, mortality, and major outcomes in primary nephrotic syndrome: the Japan Nephrotic Syndrome Cohort Study (JNSCS)Ryohei Yamamoto, Enyu Imai, Shoichi Maruyama, et al.
Clinical and Experimental Nephrology|June 21, 2020
Better remission rates in elderly Japanese patients with primary membranous nephropathy in nationwide real-world practice: The Japan Nephrotic Syndrome Cohort Study (JNSCS)Hitoshi Yokoyama, Ryohei Yamamoto, Enyu Imai, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Clinical Journal of the American Society of Nephrology : CJASN|April 12, 2014
Comparison of methylprednisolone plus prednisolone with prednisolone alone as initial treatment in adult-onset minimal change disease: a retrospective cohort studyMaki Shinzawa, Ryohei Yamamoto, Yasuyuki Nagasawa, et al.
Clinical and Experimental Nephrology|March 21, 2013
Age and prediction of remission and relapse of proteinuria and corticosteroid-related adverse events in adult-onset minimal-change disease: a retrospective cohort studyMaki Shinzawa, Ryohei Yamamoto, Yasuyuki Nagasawa, et al.
Journal of the American Society of Nephrology : JASN|January 30, 2004
The SOD mimetic tempol ameliorates glomerular injury and reduces mitogen-activated protein kinase activity in Dahl salt-sensitive ratsAkira Nishiyama, Masanori Yoshizumi, Hirofumi Hitomi, et al.
Plos One|May 17, 2011
Mutation analysis of 2009 pandemic influenza A(H1N1) viruses collected in Japan during the peak phase of the pandemicJean-Étienne Morlighem, Shintaro Aoki, Mami Kishima, et al.
Scientific Reports|June 13, 2022
Predictors of early remission of proteinuria in adult patients with minimal change disease: a retrospective cohort studyRyohei Yamamoto, Enyu Imai, Shoichi Maruyama, et al.
Journal of Nephrology|April 2, 2022
Time to remission of proteinuria and incidence of relapse in patients with steroid-sensitive minimal change disease and focal segmental glomerulosclerosis: the Japan Nephrotic Syndrome Cohort StudyRyohei Yamamoto, Enyu Imai, Shoichi Maruyama, et al.
Clinical and Experimental Nephrology|August 12, 2022
Deep learning analysis of clinical course of primary nephrotic syndrome: Japan Nephrotic Syndrome Cohort Study (JNSCS)Tomonori Kimura, Ryohei Yamamoto, Mitsuaki Yoshino, et al.
Clinical and Experimental Nephrology|April 22, 2018
Regional variations in immunosuppressive therapy in patients with primary nephrotic syndrome: the Japan nephrotic syndrome cohort studyRyohei Yamamoto, Enyu Imai, Shoichi Maruyama, et al.
Clinical and Experimental Nephrology|March 9, 2020
Incidence of remission and relapse of proteinuria, end-stage kidney disease, mortality, and major outcomes in primary nephrotic syndrome: the Japan Nephrotic Syndrome Cohort Study (JNSCS)Ryohei Yamamoto, Enyu Imai, Shoichi Maruyama, et al.
Clinical and Experimental Nephrology|June 21, 2020
Better remission rates in elderly Japanese patients with primary membranous nephropathy in nationwide real-world practice: The Japan Nephrotic Syndrome Cohort Study (JNSCS)Hitoshi Yokoyama, Ryohei Yamamoto, Enyu Imai, et al.
Pageof 2